IPPOSI retweeted
🌟 Last week, EUPATI co-organised a training session with EUPATI Ireland (@IPPOSI) on the EU HTA Regulation - the first one of 2025🎉
Stay tuned for many more training opportunities on the topic within the year! Want to take part? Register here: bit.ly/41n948l
IPPOSI retweeted
The results of the 2024 National Inpatient Experience Survey are out now!
Watch our animation to hear what patients had to say about their experiences, or read the results at yourexperience.ie.
#CareExperience
IPPOSI retweeted
Congratulations to all our Cohort 7 Graduates of the Patient Expert Training Programme!
We are very proud to have seen all of you learn, connect, collaborate, during these last four days.
#PEPT #Cohort7 #PEPT7 #EUPATI #StrongerTogether #CreatingChange #IAmEUPATIFellow
IPPOSI retweeted
The first Grá job CHI Genetics is advertised at last. Have a look? We so need this job filled. @RareDiseasesIE @22Q11_Ireland
rezoomo.com/job/71363/
IPPOSI retweeted
Derick Mitchell, Chief Executive Officer @IPPOSI, addresses the #AIForumIRL about AI in Irish healthcare
IPPOSI retweeted
Don't miss this in-person event to share knowledge on
‼️co-creating an agreement between researchers & PPI contributors‼️
Starting a #PPI group, creating an environment for #collaboration #partnership
Register: tinyurl.com/532847j6
@PPI_Ignite_TCD @hrbireland @HRCIreland
IPPOSI retweeted
Patients and the public can now find information about clinical trials being conducted in Ireland.
You can see which illnesses clinical trials are developing new treatments for, where the trials are taking place, such as in a certain hospital, and find contact details for the sponsor.
Visit the Clinical Trials Information System (CTIS) Public Portal and use the advanced search to search the database of ongoing clinical trials: euclinicaltrials.eu/search-f…
The CTIS Public Portal is part of new regulations to make clinical trial information clearer and more accessible.
#ClinicalTrialsRegulation
IPPOSI retweeted
The NCPE are seeking input from Patient Organisations for our appraisal of Ivosidenib (Tibsovo), for patients with newly diagnosed acute myeloid leukaemia, with an IDH1 R132 mutation, who are not eligible to receive standard induction chemotherapy. See: ncpe.ie/for-patients)
IPPOSI retweeted
We had a great intro session today to kick off the @IPPOSI Citizens' Jury on #AI in #healthcare. Speakers @ScanlonPatricia, @ConorJudge5 & @RBaptistaLeite were quizzed by our 25-member jury of health-interested public. More to come over the next 6 weeks ipposi.ie/aicitizensjury/
IPPOSI retweeted
Great news from EUPATI & University College Dublin 📢 🙌
UCD will sponsor their doctoral students to take our patient and public involvement courses—covering key areas like digital health, clinical development, and medical devices. 🎓💊
Learn more here:ucd.ie/ppi/learn/eupatimodul…
IPPOSI retweeted
Last chance to register for Learning Across Borders!
Featuring speakers from Ireland, Canada, Denmark and the UK discussing the opportunities and challenges to sharing knowledge about PPI experience across international borders.
Read more and register tinyurl.com/yuckcx44
IPPOSI retweeted
Great article and a really inspiring conference today. Change is happening #HSEPPP @IPPOSI @22Q11_Ireland independent.ie/irish-news/th…
IPPOSI retweeted
The NCPE are seeking input from Patient Organisations for our appraisal of zanubrutinib (Brukinsa) monotherapy for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. More details at (ncpe.ie/for-patients)
IPPOSI retweeted
Excited to announce the launch of the new national YPAG with @In4Kids.
CHI & In4kids believe children and young people should have a voice and be actively involved in design and delivery of clinical research and trials.
Check out the poster below for more info.
IPPOSI retweeted
The NCPE are seeking input from Patient Organisations for our appraisal of Pembrolizumab (Keytruda) in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced, unresectable or metastatic HER2-negative gastric..(1/2)
IPPOSI retweeted
The NCPE are seeking input from Patient Organisations for our appraisal of Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. For more details see:ncpe.ie/for-patients
IPPOSI retweeted
Register now fo our 2nd National Patient and Public Parternship Conference 2024 hsepatientconference.ie/
IPPOSI retweeted
We were delighted this week to host the second Patient Forum meeting of the year. The forum was established to provide a platform for dialogue between the HPRA and patients/patient representatives to ensure their voices are heard and incorporated into the regulation of medicines and medical devices in Ireland.
Today’s meeting focused on HPRA initiatives and supports in place that contribute to medical device innovation in Ireland. Forum members also discussed proposed updates to the Terms of Reference that acknowledge the importance of diversity and inclusion.
We would like to thank all our members for their continued support and extremely helpful contributions.
For more information on the forum please visit hpra.ie/homepage/about-us/pa….
#PatientSafety #PatientEngagement
IPPOSI retweeted
🎙️ #TheHotDesk with #MKBrazil
🚢 Dawn Meats secured a contract with a leading South Korean company.
🤖 AI in healthcare? The public has a say thanks to @IPPOSI
🏃♀️We hear from staff at @Dgfoodsltd & @MEDITESMARTPLY who are sponsors of @WVMarathon
📲 wlrfm.com